Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
Article Sidebar
Main Article Content
En Colombia la Diabetes Mellitus es un problema de salud pública por lo que deben generarse e implementarse estrategias de prevención, diagnóstico, tratamiento y seguimiento, aplicables en todos los niveles de atención con miras a establecer el control de la diabetes en forma temprana y sostenida. Se elaboró una guía de práctica clínica siguiendo los lineamientos de la guía metodológica del Ministerio de Salud y Protección Social para recolectar de forma sistemática la evidencia científica y formular las recomendaciones utilizando la metodología GRADE. El presente documento muestra, de forma resumida, el resultado de ese proceso, incluyendo las recomendaciones y las consideraciones tenidas en cuenta para llegar a ellas.
En términos generales, se propone un proceso de tamización mediante el cuestionario FINDRISC adaptado a población Colombiana que permite llegar a un diagnóstico temprano de la enfermedad y un algoritmo para el manejo inicial que es generalizable a la gran mayoría de los pacientes con DMT2 y que es sencillo de aplicar en atención primaria. También se hacen unas recomendaciones para escalar el tratamiento farmacológico de los pacientes que no alcanzan la meta o la pierden con el manejo inicial, teniendo en cuenta principalmente la evolución del peso y la individualización de la meta de control glucémico en poblaciones especiales. Finalmente se proponen algunas recomendaciones para la detección oportuna de las complicaciones micro y macrovasculares de la diabetes.
Asociación Latinoamericana de diabetes . Guias ALAD 2013 para el Diagnostico y manejo de la Diabetes Mellitus tipo 2 con medicina basada en evidencia. Rev la ALAD. 2013;
American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care [Internet]. 2013 Jan [cited 2014 May 23];36 Suppl 1(October 2012):S11–66. DOI: https://doi.org/10.2337/dc13-S011
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes : An Update Including New Drugs and 2-Drug Combinations. Ann Intern Med. 2011;154(9):602-13 DOI: https://doi.org/10.7326/0003-4819-154-9-201105030-00336
Gross JL, Kramer CK, Leita CB. Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis. Ann Intern Med. 2011 May 17;154(10):672-9 DOI: https://doi.org/10.7326/0003-4819-154-10-201105170-00007
Canadian diabetes Asociation 2013. Clinical Practice Guideline For the Prevention and Management of Diabetes in Canada. Can J diabetes. 2013; 37 Suppl 1:S1-103 DOI: https://doi.org/10.1016/S1499-2671(13)01224-0
Kahn SE, Haffner SM, Heise M a, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec;355(23):2427–43. DOI: https://doi.org/10.1056/NEJMoa066224
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364–79. DOI: https://doi.org/10.2337/dc12-0413
Dormandy J a, Charbonnel B, Eckland DJ a, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct;366(9493):1279–89. DOI: https://doi.org/10.1016/S0140-6736(05)67528-9
Handelsman Y, Mechanick JI, Dagogo-jack S, Davidson JA. AACE Guidelines. American Association of clinical endocrinologist medical guidelines for clinical practice for devoloping a diabetes mellitus comprehensive care plan. Diabetes Care. 2011;1–53.
Riethof M, Pl F, Lindvall B, Michels R, Connor OP, Redmon B, et al. Diagnosis and Management of Type 2 Diabetes Mellitus in Adults How to cite this document : Copies of this ICSI Health Care Guideline may be distributed by any organization to the organization ’ s Health Care Guideline : Diagnosis and Management of Type 2. ICSI. 2012;(April).
Phung OSJ. Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control , Weight Gain , and Hypoglycemia in Type 2 Diabetes. JAMA. 2014;303(14):1410–8. DOI: https://doi.org/10.1001/jama.2010.405
Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis NMCD. 2014 Jul;24(7):689–97. DOI: https://doi.org/10.1016/j.numecd.2014.01.017
Zhang F, Xiang H, Fan Y, Ganchuluun T-A, Kong W, Ouyang Q, et al. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine. 2013 Dec;44(3):648–58. DOI: https://doi.org/10.1007/s12020-013-9970-6
McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med . 2011 Jan;5(1):e35–48.
Liu S-C, Tu Y-K, Chien M-N, Chien K-L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012 Sep;14(9):810–20. DOI: https://doi.org/10.1111/j.1463-1326.2012.01606.x
Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res. 2013 Jul;10(4):302–14. DOI: https://doi.org/10.1177/1479164112465442
Zintzaras E, Miligkos M, Ziakas P, Balk EM, Mademtzoglou D, Doxani C, et al. Assessment of the Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis. Clin Ther. Elsevier; 2014 Aug 7;1–11. DOI: https://doi.org/10.1016/j.clinthera.2014.06.035
Sun Y-N, Zhou Y, Chen X, Che W-S, Leung S-W. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open. 2014 Jan;4(4):e004619. DOI: https://doi.org/10.1136/bmjopen-2013-004619
Bosetti C. Rosato V. Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes : Oncologist. 2013;148–56. DOI: https://doi.org/10.1634/theoncologist.2012-0302
Colmers I N. Bowker S L. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes : a meta-analysis. CMAJ. 2012;184(March):675–83. DOI: https://doi.org/10.1503/cmaj.112102
Colmers IN, Bowker SL, Johnson J a. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. Elsevier Masson SAS; 2012 Dec;38(6):475–84. DOI: https://doi.org/10.1016/j.diabet.2012.06.003
Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012 Jan;7(8):e42551. DOI: https://doi.org/10.1371/journal.pone.0042551
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; Aug 6;373(6):586. DOI: https://doi.org/10.1056/NEJMx150029
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. Elsevier Ltd; 2015;385(9982):2067–76. DOI: https://doi.org/10.1016/S0140-6736(14)62225-X
Scirica BMMM, Bhatt DLLL, Braunwald E, Steg PGGG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. DOI: https://doi.org/10.1056/NEJMoa1307684
Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366. DOI: https://doi.org/10.1136/bmj.g2366
Lincoff A, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. jama. 2014;298(10):1180–8. DOI: https://doi.org/10.1001/jama.298.10.1180
Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes Res Clin Pract [Internet]. Elsevier Ireland Ltd; 2014 Sep;105(3):313–21. DOI: https://doi.org/10.1016/j.diabres.2014.06.006
Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. DOI: https://doi.org/10.1056/NEJMoa1504720
Kong y. Shing K. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011 Jan;342:d1309. DOI: https://doi.org/10.1136/bmj.d1309
Quitian H, Aschner P, Muñoz O, Iragorri N, Girón D, Gomez-Restrepo C, et al. Economic Evaluation of Second Line Oral Antidiabetics for Type 2 Diabetes in Colombia. Value Heal. 2015;18(7):A608–9. DOI: https://doi.org/10.1016/j.jval.2015.09.2104
Downloads
- Diego Andrés Chavarro-Cavajal, Damaris Catherine Sanchez, Maria Paula Vargas-Beltrán, Luis Carlos Venegas-Sanabria, Oscar Mauricio Muñoz, Clinical value of Hospital Admission Risk Profile (HARP) and the Identification of Seniors at Risk (ISAR) scales to predict hospital-associated functional decline in an acute geriatric unit in Colombia , Colombia Medica: Vol. 54 No. 1 (2023)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use